. 2022 Mar 2;11(1):18. doi: 10.3390/antib11010018

Table 12.

An unaltered profile of HLA-Ia reactivity in the sera of six melanoma (Stage IV) patients before and 4 weeks after administering autologous melanoma cell vaccine (tumor cells treated with IFNγ were co-cultured with autologous dendritic cells in 1:1 ratio).

Mean Fluorescent Intensity (MFI) of Anti-HLA-Ia IgG Antibodies in Melanoma Patients before and 4 Weeks after Autologus Whole Cell Cancer Vaccine
Patient ID	Before and after 4 Wks Post vaccine	E^R*0101	HLA-B Reactivity																							HLA-C Reactivity
Patient ID	Before and after 4 Wks Post vaccine	E^R*0101	B*0702	B*1301	B*1401	B*1512	B*1516	B*2705	B*2705	B*2708	B*3701	B*4001	B*4002	B*4006	B*4201	B*4402	B*4701	B*5401	B*5501	B*5601	B*5701	B*5703	B*6701	B*8101	B*8201	C*0101	C*0202	C*0302	C*0303	C*0304	C*0401	C*0501	C*0602	C*0702	C*0801	C*1203	C*1402	C*1502	C*1601	C*1701	C*1801
HCC-1763	PreVax	550																																					590
HCC-1763	PostVax	830																																					1330
HCC-1766	PreVax	3140
HCC-1766	PostVax	3830								700
HCC-1937	PreVax	3710
HCC-1937	PostVax	4040									570																940	650		550			670							1107
HCC-1896	PreVax	3710	3340					1490	1740			1080	980		1430				1150	820			1210	3250	1170
HCC-1896	PostVax	4520	3610					1720	1820			990	1030		1480				1190	830			1240	3460	1210
HCC-2030	PreVax	1650			540	12,330	1180				540			530		8760	540	570			3460	6180	540		6140	750	750	930	500		700	2180	950	1500		660		600		1830	910
HCC-2030	PostVax	8620		640	1230	12,700	2240				790			760		9040	830	950			3190	5520	670		5340	1580	1340	1901	1030	690	1330	2560	1690	2940	650	1240		630		2730	1300
HCC-1957	PreVax	3870			540		640				1250							570									1080	1020			540		770	1150		580				560
HCC-1957	PostVax	4990			1050		1370				2550							1170									2250	1933	700	1620	880		1370	2040		850				850